## Cadila Healthcare Ltd. - Consolidated Break-up of Gross Sales

Rs. Mio.

Rs. Mio.	YTD	YTD	% Gr
	09-10	08-09	у-у
Domestic	18,724	16,435	13.9%
Formulations	14,458	12,889	12.2%
Branded Formulations	13,625	12,146	12.2%
Generic Formulations	833	743	12.2%
API	318	426	-25.4%
Consumer & Others	3,948	3,120	26.5%
Consumer Products	2,675	1,947	37.4%
Animal Health & Others	1,273	1,173	8.5%
Exports	17,418	12,736	36.8%
Formulations	14,018	9,676	44.9%
North America	6,715	3,984	68.6%
Europe	2,740	2,094	30.9%
Latin America	1,818	1,628	11.6%
Japan	316	219	43.9%
Emerging Markets	1,590	1,750	-9.1%
Zydus Hospira (50%)	839	0	
API	3,400	3,060	11.1%
Zydus Nycomed (50%)	758	999	-24.1%
Others	2,642	2,061	28.2%
Total	36,142	29,171	23.9%

## Cadila Healthcare Ltd. - Consolidated Other Details pertaining to FY 09-10

Rs. Mio.

R&D Expenses	YTD 09-10	YTD 08-09	% Gr y-y
R&D Revenue Expenses	1,660	1,564	6.1%
R&D Capex	415		

Other Incomes	YTD	YTD	% Gr
	09-10	08-09	у-у
A. Operating Income			
a. Export Incentive	91	89	2.2%
b. Processing Income	401	352	13.9%
c. Royalty Income	288		
d. Others	347	210	65.3%
Total Operating Income	1,127	651	73.0%
B. Other Income			
a. Dividend	1	4	-76.7%
b. Interest Income	145	99	46.4%
c. Rent received	12	12	-6.5%
d. Profit on sale of assets	2	89	-98.0%
Total Other Income	159	204	-22.0%

Exceptional Items	YTD 09-10	YTD 08-09
Compensation under Voluntary		
Retirement Scheme (in Brazil and	24	97
Liva Healthcare)		
Expenses incurred on Composite		
Scheme of Arrangement (in Zydus	22	144
Wellness Ltd.)		
Total	46	241

Consolidated Capex for FY 09-10	Rs. 3247
(Excl. Goodwill)	Mio.